Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 11/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | DRD4 | P21917 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | ALPL | P05186 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899104 | 0.87 | ADRB2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| SCHEMBL5899114 | 0.87 | ADRB2 (0.76) | TBXA2RADRB2GAAADRB1ADRB3 | |
| SCHEMBL5899119 | 0.86 | ADRB2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| SCHEMBL5899094 | 0.79 | ADRB2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| SCHEMBL16602137 | 0.78 | DRD2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| SCHEMBL29375567 | 0.78 | DRD2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| SCHEMBL221137 | 0.78 | DRD2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| SCHEMBL29373547 | 0.78 | DRD2 (1.00) | TBXA2RADRB2DRD2DRD4MEN1 | |
| Hydrochloric Acid SCHEMBL5899124 | 0.78 | TBXA2R (0.98) | TBXA2RADRB2DRD2DRD4MEN1 | |
| Bromide SCHEMBL3276906 | 0.76 | DRD2 (0.97) | TBXA2RADRB2DRD2DRD4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119103-B2 | β3-Adrenoreceptor agonists, agonist compositions and methods of using | MOLECULAR DESIGN INTERNATIONAL, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050096347-A1 | Beta3-Adrenoreceptor agonists, agonist compositions and methods of using | MOLECULAR DESIGN INTERNATIONAL, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6825213-B2 | NITROGEN COMPOUNDS SUCH AS 1-(4-AMINO-3,5-DIIODOBENZYL)-6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE, USED AS ADRENERGIC STIMULANTS FOR PROPHYLAXIS OF METABOLIC DISORDERS; OBESITY | MOLECULAR DESIGN INTERNATIONAL, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040019079-A1 | Beta3-Adrenoreceptor agonists, agonist compositions and methods of using | FELLER DENNIS R (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1023269-A4 | BETA3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USING | MOLECULAR DESIGN INT (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1023269-A1 | BETA3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USING | MOLECULAR DESIGN INTERNATIONAL, INC. (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999016752-A1 | β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USING | MOLECULAR DESIGNS INTERNATIONAL, INC. (US) | 1999-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096347-A1 | Beta3-Adrenoreceptor agonists, agonist compositions and methods of using | ADRB3, ADRB1, ADRB2 | TBXA2R 29/4885ADRB2 3/4885DRD2 666/4885 |
| US-20040019079-A1 | Beta3-Adrenoreceptor agonists, agonist compositions and methods of using | ADRB3, ADRB1, ADRB2 | TBXA2R 30/4885ADRB2 3/4885DRD2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.